Skip to content

    Cancer Health Center

    Font Size

    Sutent, Tykerb May Curb Liver Cancer

    Studies Show Drugs May Help Treat Advanced Liver Cancer
    WebMD Health News
    Reviewed by Louise Chang, MD

    April 16, 2008 (San Diego) -- Two anticancer drugs show promise for treating people with advanced liver cancer, one of the deadliest types of cancers.

    One drug, Sutent, stopped tumor growth and spread in about half of people with advanced liver cancer.

    In a second study, a once-a-day pill called Tykerb halted tumor growth in about one-third of patients.

    People with advanced liver cancer have very few options, says Andrew X. Zhu, MD, PhD, director of liver cancer research at Massachusetts General Hospital Cancer Center in Boston.

    Nexavar is the only medication that's been shown to extend their lives, he says. It was approved by the FDA in November after a large study showed people with advanced liver cancer given Nexavar lived about three months longer than those given a placebo: 10.7 months vs. 7.9 months.

    Enter Sutent, which puts the brakes on the growth of tumor-feeding blood vessels and deprives tumor cells of blood and nutrients needed for growth.

    It is part of a class of drugs called tyrosine kinase inhibitors. It's already approved to treat advanced kidney cancer and recalcitrant gastrointestinal stromal tumors (GIST).

    Sutent Halts Tumor Growth

    The study involved 34 patients with advanced liver cancer. They took one Sutent pill a day for four weeks. Then they took a drug holiday for two weeks and repeated the cycle.

    The findings were presented here at the annual meeting of the American Association for Cancer research.

    By 12 weeks after starting treatment, the tumor shrank in only one patient. But 17 patients had stable disease -- "that is, tumor growth had stopped and they were doing well clinically," Zhu says.

    Patients lived an average of 10 months.

    Importantly, molecular markers showed clear evidence that the drug was associated with antitumor activity, Zhu says.

    The treatment was safe, he adds. Common side effects included elevated liver enzymes, low levels of certain blood cells, and fatigue.

    Christopher Willett, MD, head of radiation oncology at Duke University in Durham, N.C., tells WebMD that the findings are "preliminary, but encouraging."

    The fact that there was evidence of changes in molecular markers that signal better outcome is particularly noteworthy, Willett says.

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
    Jennifer Goodman Linn self-portrait
    what is your cancer risk
    colorectal cancer treatment advances
    breast cancer overview slideshow
    prostate cancer overview
    lung cancer overview slideshow
    ovarian cancer overview slideshow
    Actor Michael Douglas